Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination.

"Potential conflicts of interest. S. J. received grants from the Dutch research council (NWO), European Union Horizon 2020, and the Bill and Melinda Gates Foundation. W. F. W. B. declares reimbursement to institution for participation of patient in trial by GSK. R. D. d. V. is listed as inventor of the fusion inhibitory lipopeptide [SARSHRC-PEG4]2-chol on a provisional patent application. K. C. E. S. received honorariums for advisory boards from Gilead and ViiV. C. R. has received research grants from ViiV, Gilead, ZonMw, AIDSfonds, Erasmus MC, and Health∼Holland; and honorariums for advisory boards from Gilead and ViiV. B. J. A. R. declares research grants from Gilead and MSD; and honorary for advisory boards for AstraZeneca, Roche, Gilead, and F2G. K. B. received research and educational grants from ViiV and Gilead; and consulting fees for advisory boards for ViiV, Gilead, MSD, and AstraZeneca. A. R. received grants from the Bill and Melinda Gates foundation and the Leids Universitair Fonds. All other authors report no potential conflicts of interest.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

"Financial support. This work was supported by the Netherlands Organization for Health Research and Development (ZonMw) (grant number 10430072010008); and Health∼Holland (grant number EMCLHS20017 to D. G. and R. D. d. V.) cofunded by the PPP Allowance made available by the Health∼Holland, Top Sector Life Sciences and Health, to stimulate public-private partnerships. Financial support."

"Clinical Trials Registration . EUCTR2021-001054-57-N."